Trastuzumab Deruxtecan
Antibody–drug conjugate
Also known as DS-8201
Evidence outlook
Approved: Non-Small Cell Lung Cancer, HR+/HER2- Metastatic Breast Cancer (label: HER2-low and HER2-ultralow metastatic breast cancer, HR-positive or HR-negative, after prior...), Breast Cancer, HER2-Positive Breast Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (4)
- HER2-Low and HER2-Ultralow Metastatic Breast Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic Hormone receptor (HR)-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-authorized test, that has progressed on one or more endocrine therapies in the metastatic setting [see Dosage and Administration (2.1) ] . HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-authorized test, who have received a prior chemotherapy in the metastatic settin
- HER2-Positive Locally Advanced or Metastatic Gastric Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
- Enhertu (with pertuzumab): 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
- Breast cancerHER2-positive breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.HER2-low and HER2-ultralow breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04494425 NCT04494425 · HR+/HER2- Metastatic Breast Cancer The trial was large and randomized, with an active chemotherapy comparator and a hard clinical primary endpoint of progression-free survival, which was met: median PFS was 13.2 versus 8.1 months, with HR 0.62 and p<0.0001. However, treatment assignment was not blinded, so despite the strong randomized result this is considered moderate evidence rather than strong evidence. Registry: NCT04494425 | 3 | Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)) 2024-03-18 | Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9) | Partial signal | link ↗ |
View 1 more trial
NCT03734029 NCT03734029 · HR+/HER2- Metastatic Breast Cancer This was a randomized, parallel-group phase 3 trial of 557 people with an active chemotherapy comparator, and the primary endpoint of progression-free survival was clearly met (p<0.0001). However, the study was open-label, with no masking of patients or investigators, so knowledge of the assigned treatment could have influenced care and assessment. Progression was judged by a blinded independent central review, which limits but does not remove that concern. Registry: NCT03734029 | 3 | Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years) 2022-01-11 | Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (23)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (70)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (23)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (23)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (7)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (5)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
Other HER2 drugs
margetuximab, Tucatinib, Zanidatamab, Disitamab Vedotin, Trastuzumab brengitecan and 11 more. Compare all 17 HER2 drugs
This mechanism is crowded: 16 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for HER2-Positive Breast Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Trastuzumab Deruxtecan: this drug | Approved | Antibody–drug conjugate | HER2 | Partial signal | NCT03523585: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8) | |
| Margetuximab (Margenza) | Approved | Monoclonal antibody | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Neratinib | Approved | Small molecule | EGFR/HER2 | Reliable signal | NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events | |
| Palbociclib (Ibrance) | Approved | Small molecule | CDK4 and CDK6 | not yet graded | No reviewed efficacy summary in this indication | |
| Pertuzumab | Approved | Monoclonal antibody | HER2/neu Receptor Antagonist | Reliable signal | NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016). NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results). | |
| Trastuzumab Emtansine | Approved | Antibody–drug conjugate | HER2 (ERBB2) | Partial signal | Featured results are non-efficacy only in this race | |
| Tucatinib | Approved | Small molecule | HER2 | Reliable signal | NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001. NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1) | |
| Anbenitamab Repodatecan | Phase 3 | Antibody–drug conjugate | HER2 (biparatopic — extracellular domains II and IV) | not yet graded | No reviewed efficacy summary in this indication | |
| Docetaxel (HB1801) | Phase 3 | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Pyrotinib | Phase 3 | Small molecule | EGFR/HER1, HER2, HER4 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Pamirtecan | Phase 3 | Antibody–drug conjugate | HER2 | Partial signal | NCT06265428: NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanidatamab | Phase 3 | Multispecific antibody | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Bizrolertinib | Phase 2/3 | Small molecule | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Disitamab Vedotin | Phase 2/3 | Antibody–drug conjugate | HER2 | Partial signal | NCT03500380: Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91). | |
| Evorpacept | Phase 2 | Protein / enzyme therapeutic | CD47 | not yet graded | No reviewed efficacy summary in this indication | |
| BBO-10203 | Phase 1(overall) | Small molecule | RAS:PI3Kα protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| RAD202 | Phase 1(overall) | Radiopharmaceutical | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
9 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(101 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Trastuzumab Deruxtecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (4)
November 2026 (1)
What to watch
December 2026 (3)
What to watch
What to watch
What to watch
2027 (43)
January 2027 (3)
What to watch
What to watch
What to watch
February 2027 (1)
What to watch
March 2027 (3)
What to watch
What to watch
What to watch
April 2027 (4)
What to watch
What to watch
What to watch
What to watch
May 2027 (4)
What to watch
What to watch
What to watch
What to watch
June 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (1)
What to watch
August 2027 (2)
September 2027 (4)
What to watch
What to watch
What to watch
What to watch
October 2027 (4)
What to watch
What to watch
What to watch
What to watch
November 2027 (3)
What to watch
What to watch
What to watch
December 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (29)
January 2028 (4)
What to watch
What to watch
What to watch
What to watch
February 2028 (2)
March 2028 (2)
What to watch
What to watch
May 2028 (1)
What to watch
June 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
July 2028 (3)
What to watch
What to watch
What to watch
August 2028 (1)
What to watch
September 2028 (2)
What to watch
What to watch
October 2028 (2)
November 2028 (3)
What to watch
What to watch
What to watch
December 2028 (4)
What to watch
What to watch
What to watch
What to watch
2029 (11)
January 2029 (2)
February 2029 (1)
What to watch
April 2029 (2)
May 2029 (1)
What to watch
June 2029 (1)
What to watch
July 2029 (1)
What to watch
August 2029 (1)
What to watch
2030 (11)
February 2030 (1)
What to watch
March 2030 (2)
April 2030 (1)
What to watch
June 2030 (1)
July 2030 (1)
What to watch
September 2030 (1)
What to watch
November 2030 (1)
What to watch
December 2030 (3)
What to watch
What to watch
What to watch
2032 (1)
May 2032 (1)
What to watch
2033 (1)
February 2033 (1)
What to watch
2036 (1)
March 2036 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent